[1] [1] FOKKENS W J, LUND V J, HOPKINS C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl S29): 1-464. DOI: 10.4193/Rhin20.600.

[2] [2] LIU X D, CHARN T C, WANG D Y. Mepolizumab in chronic rhinosinusitis with nasal polyposis[J]. Immunotherapy, 2023, 15(14): 1105-1116. DOI: 10.2217/imt-2023-0026.

[3] [3] LOFTUS C A, SOLER Z M, KOOCHAKZADEH S, et al. Revision surgery rates in chronic rhinosinusitis with nasal polyps: meta-analysis of risk factors[J]. Int Forum Allergy Rhinol, 2020, 10(2): 199-207. DOI: 10.1002/alr.22487.

[4] [4] ORLANDI R R, KINGDOM T T, SMITH T L, et al. International consensus statement on allergy and rhinology: rhinosinusitis 2021[J]. Int Forum Allergy Rhinol, 2021, 11(3): 213-739. DOI: 10.1002/alr.22741.

[6] [6] MANDL H K, MILLER J E, BESWICK D M. Current and novel biologic therapies for patients with asthma and nasal polyps[J]. Otolaryngol Clin North Am, 2024, 57(2): 225-242. DOI: 10.1016/j.otc.2023.08.006.

[7] [7] HAMILTON D, LEHMAN H. Asthma phenotypes as a guide for current and future biologic therapies[J]. Clin Rev Allergy Immunol, 2020, 59(2): 160-174. DOI: 10.1007/s12016-019-08760-x.

[8] [8] YAO Y, ZENG M, LIU Z. Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics[J]. Clin Exp Allergy, 2022, 52(2): 231-243. DOI: 10.1111/cea.14065.

[9] [9] ZHANG Y, GEVAERT E, LOU H F, et al. Chronic rhinosinusitis in Asia[J]. J Allergy Clin Immunol, 2017, 140(5): 1230-1239. DOI: 10.1016/j.jaci.2017.09.009.

[10] [10] GEVAERT P, HAN J K, SMITH S G, et al. The roles of eosinophils and interleukin-5 in the pathophysiology of chronic rhinosinusitis with nasal polyps[J]. Int Forum Allergy Rhinol, 2022, 12(11): 1413-1423. DOI: 10.1002/alr.22994.

[11] [11] TOMASSEN P, VANDEPLAS G, VAN ZELE T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J]. J Allergy Clin Immunol, 2016, 137(5): 1449-1456. e4. DOI: 10.1016/j.jaci.2015.12.1324.

[12] [12] BACHERT C, NAN Z, CAVALIERE C, et al. Biologics for chronic rhinosinusitis with nasal polyps[J]. J Allergy Clin Immunol, 2020, 145(3): 725-739. DOI: 10.1016/j.jaci.2020.01.020.

[13] [13] TOMASSEN P, VANDEPLAS G, VAN ZELE T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers[J]. J Allergy Clin Immunol, 2016, 137(5): 1449-1456. e4. DOI: 10.1016/j.jaci.2015.12.1324.

[14] [14] GEVAERT P, VAN BRUAENE N, CATTAERT T, et al. Mepolizumab, a humanized anti-IL-5 MAb, as a treatment option for severe nasal polyposis[J]. J Allergy Clin Immunol, 2011, 128(5): 989-995.e1-8. DOI: 10.1016/j.jaci.2011.07.056.

[15] [15] BACHERT C, SOUSA A R, LUND V J, et al. Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial[J]. J Allergy Clin Immunol, 2017, 140(4): 1024-1031.e14. DOI: 10.1016/j.jaci.2017.05.044.

[16] [16] HAN J K, BACHERT C, FOKKENS W, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Respir Med, 2021, 9(10): 1141-1153. DOI: 10.1016/S2213-2600(21)00097-7.

[17] [17] STACK T J, KIM S, LAMB M M, et al. Characterizing adverse events of biologic treatment of T2 disease: a disproportionality analysis of the FDA adverse event reporting system[J]. ORL J Otorhinolaryngol Relat Spec, 2023, 85(6): 329-339. DOI: 10.1159/000534545.

[18] [18] KARIYAWASAM H H, JAMES L K. Chronic rhinosinusitis with nasal polyps: targeting IgE with anti-IgE omalizumab therapy[J]. Drug Des Devel Ther, 2020, 14: 5483-5494. DOI: 10.2147/DDDT.S226575.

[19] [19] GEVAERT P, OMACHI T A, CORREN J, et al. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials[J]. J Allergy Clin Immunol, 2020, 146(3): 595-605. DOI: 10.1016/j.jaci.2020.05.032.

[20] [20] KARIYAWASAM H H. Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4R inhibition with dupilumab[J]. Expert Rev Clin Immunol, 2020, 16(12): 1115-1125. DOI: 10.1080/1744666X.2021.1847083.

[21] [21] BACHERT C, HAN J K, DESROSIERS M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (liberty np sinus-24 and liberty np sinus-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials[J]. Lancet, 2019, 394(10209): 1638-1650. DOI: 10.1016/S0140-6736(19)31881-1.

[22] [22] WU Q W, ZHANG Y N, KONG W F, et al. Which is the best biologic for nasal polyps: dupilumab, omalizumab, or mepolizumab? A network meta-analysis[J]. Int Arch Allergy Immunol, 2022, 183(3): 279-288. DOI: 10.1159/000519228.

[23] [23] OYKHMAN P, PARAMO F A, BOUSQUET J, et al. Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis[J]. J Allergy Clin Immunol, 2022, 149(4): 1286-1295. DOI: 10.1016/j.jaci.2021.09.009.

[24] [24] YONG M, KIRUBALINGAM K, DESROSIERS M Y, et al. Cost-effectiveness analysis of biologics for the treatment of chronic rhinosinusitis with nasal polyps in Canada[J]. Allergy Asthma Clin Immunol, 2023, 19(1): 90. DOI: 10.1186/s13223-023-00823-1.

[25] [25] ANDERSON W C 3rd, SZEFLER S J. Cost-effectiveness and comparative effectiveness of biologic therapy for asthma: To biologic or not to biologic?[J]. Ann Allergy Asthma Immunol, 2019, 122(4): 367-372. DOI: 10.1016/j.anai.2019.01.018.

[26] [26] WANG X D, ZHANG N, BO M Y, et al. Diversity of TH cytokine profiles in patients with chronic rhinosinusitis: a multicenter study in Europe, Asia, and Oceania[J]. J Allergy Clin Immunol, 2016, 138(5): 1344-1353. DOI: 10.1016/j.jaci.2016.05.041.

[27] [27] YAO Y, ZENG M, LIU Z. Revisiting Asian chronic rhinosinusitis in the era of type 2 biologics[J]. Clin Exp Allergy, 2022, 52(2): 231-243. DOI: 10.1111/cea.14065.